The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Home monitoring tools for GLP-1 therapy can help track progress and identify issues early
Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, Vissing J
In seven large cardiovascular studies, all agents shown at least non-inferiority, with liraglutide, subcutaneous semaglutide, and dulaglutide revealing statistically significant decreases in cardiovascular outcomes (Sheahan et al
Special Supplemental Nutrition Program for pregnant, breastfeeding, postpartum women, infants and children up to age 5
Laboratory Safety Protocols General chemical safety practices should be followed when handling research peptides